microRNAs (miRNAs) play key roles in modulating a variety of cellular processes through repression of mRNA targets. In a screen for miRNAs regulated by myocardin-related transcription factor-A (MRTF-A), a coactivator of serum response factor (SRF), we discovered a muscle-enriched miRNA, miR-486, controlled by an alternative promoter within intron 40 of the Ankyrin-1 gene. Transcription of miR-486 is directly controlled by SRF and MRTF-A, as well as by MyoD. Among the most strongly predicted targets of miR-486 are phosphatase and tensin homolog (PTEN) and Foxo1a, which negatively affect phosphoinositide-3-kinase (PI3K)/Akt signaling. Accordingly, PTEN and Foxo1a protein levels are reduced by miR-486 overexpression, which, in turn, enhances PI3K/Akt signaling. Similarly, we show that MRTF-A promotes PI3K/Akt signaling by up-regulating miR-486 expression. Conversely, inhibition of miR-486 expression enhances the expression of PTEN and Foxo1a and dampens signaling through the PI3K/Akt-signaling pathway. Our findings implicate miR-486 as a downstream mediator of the actions of SRF/MRTF-A and MyoD in muscle cells and as a potential modulator of PI3K/Akt signaling.
Akt signaling | microRNA | muscle growth | myocardin related transcription factor-A | cardiomyocyte m icroRNAs (miRNAs) play key roles in a broad range of biological processes, and in many cases have been shown to modulate intracellular signaling pathways involved in development and disease (1) . miRNAs inhibit translation or promote mRNA degradation by annealing to complementary sequences in mRNA 3′ untranslated regions (UTRs). Individual miRNAs typically target dozens of mRNAs, often encoding proteins with related functions. Thus, although their inhibitory effects on individual mRNAs are generally modest, their combined effects on multiple mRNAs can evoke strong biological responses. miRNAs play especially powerful roles in muscle cells, where they have been implicated in cell fate specification, proliferation, differentiation, and stress responsiveness (2) (3) (4) .
Members of the myocardin family of transcription factors control growth and development of cardiac, skeletal, and vascular smooth muscle cells, as well as their responses to physiological and pathological signaling (5) (6) (7) (8) . Myocardin and myocardin-related transcription factors (MRTFs) are recruited to downstream target genes through interaction with serum response factor (SRF). Recently, we discovered that MRTFs directly activate the transcription of a cardiovascular-specific miRNA cluster encoding miR-143 and miR-145 (9) . These miRNAs, in turn, regulate multiple modulators of actin dynamics and SRF function, thereby influencing smooth muscle growth and responsiveness to mechanical stimuli.
Here we show that MRTF-A also regulates the expression of miR-486, a muscle-enriched miRNA encoded by intron 40 of the Ankyrin-1 (Ank-1) gene. Among the targets of miR-486 are the mRNAs encoding PTEN and Foxo1a, which serve as negative components of phosphoinositide-3-kinase (PI3K)/Akt signaling. Through gain-and loss-of-function experiments, we show that miR-486 modulates PI3K/Akt signaling by directly targeting phosphatase and tensin homolog (PTEN), an inhibitor of PI3K phosphorylation, thereby promoting the phosphorylation of Akt and the activity of downstream components of the pathway. Consistent with a role for MRTF-A in the regulation of this signaling pathway via miR-486, MRTF-A enhances PI3K/Akt signaling in cardiomyocytes, an effect that is blunted by inhibition of miR-486 expression. Our findings reveal a role for miR-486 as an intermediary between MRTF-A and the PI3K/Akt-signaling pathway and suggest the potential involvement of miR-486 in regulating muscle growth and homeostasis.
Results
Regulation of miR-486 by MRTF-A. In an effort to identify miRNAs that mediate the actions of MRTF-A and its partner SRF in muscle cells, we performed microarray analysis to compare the miRNA expression profiles of neonatal rat cardiomyocytes (CMCs) infected with adenoviruses expressing MRTF-A or β-galactosidase as a control (Fig. S1 ). Among several miRNAs that were up-regulated by MRTF-A (9), miR-486 showed the most dramatic increase in expression in MRTF-A-transduced CMCs. The induction of miR-486 by MRTF-A was confirmed by Northern blot and real-time RT-PCR ( Fig. 1 A and B) .
miR-486 is a unique miRNA with no known family members and is conserved in mammals, but does not exist in birds, fish, amphibians, or lower metazoans. miR-486 is transcribed from an intron of the Ank1 gene ( Fig. 1C and Fig. S2 ), which encodes an ankyrinrepeat protein that links the cytoskeleton to the plasma membrane. Ank1 is expressed specifically in erythroid cells under control of an erythroid-specific promoter (Fig. 1C and ref. 10 ). The final three exons (exons 40-42) of the Ank1 gene, preceded by an alternative exon (exon 39a), code for a muscle-specific Ank1 protein, referred to as small Ank1 (sAnk1), which connects the sarcomere to the sarcoplasmic reticulum (11) .
The expression of the sAnk1 transcript is regulated by an alternative promoter immediately upstream of exon 39a of the Ank1 gene, which contains two conserved E-boxes that confer responsiveness to MyoD (Fig. 1C) (12, 13) . Genomic sequence upstream and within the first intron of the sAnk1 gene also contains putative binding sites for SRF [CC(A/T) 6 GG], referred to as CArG boxes, which may mediate responsiveness to MRTF-A (Fig. 1C and Fig.  S3 ). Like miR-486, sAnk1 was also induced in CMCs by MRTF-A (Fig. 1B) . The coregulation of miR-486 and sAnk1 suggests that miR-486 is generated by the processing of Ank1 intronic RNA.
Expression of miR-486 and sAnk1 in Cardiac and Skeletal Muscle. We examined the expression of miR-486 and sAnk1 by Northern blot and RT-PCR, respectively, to compare their tissue distribution. miR-486 is enriched in cardiac and skeletal muscle ( Fig. 2A and Fig. S4 ), as previously reported for sAnk1 (12) . The tissue dis-tribution of sAnk1 transcripts recapitulated the cardiac and skeletal muscle expression of miR-486 ( Fig. 2A) .
By in situ hybridization with a probe designed against the sAnk1-specific exon 39a, sAnk1 transcripts were initially detected specifically in the somites at embryonic day (E)11.5 (Fig. 2B) . By E12.5, sAnk1 expression was observed throughout the skeletal muscle of the tongue, diaphragm, and the myotome layer of the somites, but not in the heart (Fig. 2B ). We first observed cardiac expression of sAnk1 at E17.5, specifically in the atrial chambers, the atrio-ventricular (AV) node, and the bundle branches in the trabecular layer of the ventricles (Fig. 2B ). Atrial and AV node expression became more robust by postnatal day 1 (P1), and ventricular expression became detectable by P5 (Fig. S5) . The adult heart displayed sAnk1 expression throughout all cardiac chambers (Fig. 2B) . We conclude that miR-486 is a skeletal muscle and cardiac-enriched miRNA, which is coexpressed with sAnk1.
Regulation of sAnk1/miR-486 by MRTF-A. We examined noncoding DNA upstream and within the first intron of the sAnk1 gene for the ability to direct MRTF-A-dependent transcription. A luciferase reporter linked to 1080 bp of genomic DNA upstream of alternate exon 39a displayed strong responsiveness to MyoD in transfected COS cells (Fig. 3A) . Mutation of two E-boxes in this genomic fragment completely abolished MyoD directed promoter activity (Fig.  3A) . In contrast, MRTF-A failed to activate this reporter (Fig. 3A) , despite the presence of a putative CArG box, suggesting that cisregulatory elements responsible for MRTF-A responsiveness are located elsewhere.
Both mouse and human sAnk1 contain CArG-like sequences in intron 39a (Fig. 1C and Fig. S3 ). Like the endogenous gene, the sAnk1 intron-luciferase reporter was responsive to MRTF-A in COS cells (Fig. 3B) . Mutation of CArG1 reduced responsiveness to MRTF-A, and a CArG2 mutation nearly abolished transcriptional activity (Fig. 3B) . A 3′ truncation of the intron to ∼300 bp, which contains only CArG1, also resulted in a pronounced loss of reporter activity. The intronic reporter was also responsive to adenoviral-expressed MRTF-A in CMCs, whereas constructs containing a 3′ truncation of the intron or a mutation of either CArG1 or CArG2 were not induced by MRTF-A (Fig. 3C) . The upstream reporter was not responsive to MRTF-A, further suggesting that the upstream CArG is not functional (Fig. 3C) .
In gel mobility shift assays, SRF bound efficiently and specifically to both intronic CArG sequences, and unlabeled CArG oligonucleotide effectively competed for SRF binding, whereas a mutant CArG oligonucleotide did not compete for binding (Fig. 3D) . We conclude that the first intron of the sAnk1 gene contains two functional CArG boxes that are required to direct responsiveness to SRF/MRTF-A in transient transfection assays.
Regulation of sAnk1/miR-486 Transcription in Cardiac and Skeletal
Muscle. To identify cis-regulatory elements responsible for muscle-specific expression in vivo, we generated transgenic mice harboring a lacZ reporter controlled by upstream and intronic genomic regions of sAnk1/miR-486. Consistent with the responsiveness of the 1080-bp upstream region to MyoD in vitro, this genomic region directed lacZ activity in muscle cells within developing somites by E11.5 and throughout skeletal muscles at E13.5 and into adulthood (Fig. 4 A and C) . However, this regulatory region was inactive in the heart at all embryonic and adult time points examined. The fulllength intron did not direct expression in heart or skeletal muscle, but the ∼300-bp 3′ truncated intron, which contains only the proximal CArG1, directed robust expression in adult skeletal muscle and in the atria and the AV canal of the heart, partially recapitulating endogenous sAnk1/miR-486 expression ( (i ) sAnk1 is observed specifically in the developing somites and limb muscles of a whole-mount E11.5 embryo; head staining is nonspecific. Radioactive-section in situ hybridization demonstrates sAnk1 expression at E12.5 (ii ) and in the embryonic and adult heart (iii and iv).
(ii ) sAnk1 is robustly expressed in the somites, tongue, facial muscles, and diaphragm. Expression within the heart is localized to the atria, AV node, and bundle branches at E17.5 (iii ). sAnk1 expression is observed throughout all cardiac chambers in the adult heart (iv). (Scale bar: 1 mm.) at, atrium; avn, atrioventricular node; bb, bundle branches; di, diaphragm; fm, facial muscles; lm, limb muscle; s, somites; tg, tongue; v, ventricle.
muscle ( Fig. 4C ), further suggesting that SRF and MRTF-A contribute to the postnatal muscle-specific expression of miR-486.
Targeting of the PI3K/Akt-Signaling Pathway by miR-486. To begin to decipher the functions of miR-486, we searched for evolutionarily conserved, predicted mRNA targets of this miRNA. Multiple positive and negative components of the PI3K/Akt-signaling pathway, including PTEN, Foxo1a, PI3KRα (p85α), and insulin-like growth factor 1 (IGF1) are among the strongest predicted targets of miR-486 using the TargetScan5.0 and miRanda algorithms (Table S1 ). Activation of the PI3K/Akt-signaling pathway by IGF1 results in the phosphorylation of Akt and the promotion of muscle growth and survival via the inactivation of glycogen synthase3β (GSK3β) and Foxo1 (14, 15) . PTEN is a PI3K-specific phosphatase that inactivates the Akt-signaling pathway, functioning as a potent inhibitor of growth and survival signaling (16) . Examination of the expression levels of miR-486 and the protein levels of components of the PI3K/Akt-signaling pathway at various postnatal time points revealed an inverse correlation between expression of miR-486 and PTEN in the maturing heart (Fig. 5A) . miR-486 was elevated ≈10-fold in the ventricles between birth and 4 weeks of age, whereas PTEN protein levels decreased ∼40% over the same time period (Fig. 5 A and B) . These findings suggested an intriguing physiological relationship between miR-486 and PTEN concomitant with a time of dramatic postnatal cardiac growth, potentially implicating miR-486 in a molecular pathway controlling muscle growth. In line with the observed correlation of miR-486 expression and muscle growth, the expression of miR-486 and its host Number of transgenic embryos displaying muscle-specific expression per total number of transgenic embryos is shown in right columns. Embryonic and adult expression was assessed in F 0 transgenics and stable transgenic lines. The 1,080-bp upstream reporter containing the two E-boxes directed embryonic and adult skeletal muscle expression, but was insufficient for cardiac expression. The full-length intron reporter, containing two CArG boxes, was insufficient to direct expression in transgenic mice; however, a truncated intron consisting of the 5′ most 300 bp and a single CArG box directed adult skeletal muscle and heart expression. Mutation of the single CArG box within the truncated intron abolished lacZ expression in the skeletal muscle and heart. gene, sAnk1, was decreased in atrophied skeletal muscle following surgical denervation (Fig. S7) .
Because miR-486 is expressed in a manner more consistent with promotion of muscle growth or inhibition of muscle atrophy and is correlated with decreased PTEN protein levels, we examined the potential of miR-486 to directly target the 3′ UTRs of PTEN and Foxo1a, two critical negative components of the Akt-signaling cascade. The 3′ UTRs of PTEN and Foxo1a mRNAs each contain thermodynamically stable predicted binding sites for miR-486 (Table S1 and Fig. S8 ). Luciferase reporter constructs linked to the 3′ UTRs of either the PTEN or Foxo1a mRNAs were repressed by cotransfection of miR-486 expression plasmid (Fig. 5C) . Mutation of the miR-486 binding sites abrogated the repression of the luciferase reporter construct (Fig. 5C) .
To test more directly the potential involvement of miR-486 in the process of Akt signaling, we asked whether overexpression of miR-486 in CMCs was sufficient to activate Akt signaling. Adenoviral-mediated overexpression of miR-486 resulted in ≈10-fold higher levels of miR-486 than in control-infected CMCs (Fig. 5D) . Concomitant with elevated miR-486 levels, we observed a reduction of PTEN protein levels and phosphorylation of Akt at Ser-473 (Fig. 5E) , a site responsible for Akt activation. These results implicate miR-486 in the activation of PI3K/Akt signaling by inhibiting PTEN.
MRTF-A Activates PI3K/Akt Signaling via miR-486 Induction. The ability of MRTF-A to up-regulate miR-486, which, in turn, inhibits PTEN, a negative regulator of the PI3K/Akt pathway, suggested that MRTF-A might stimulate Akt signaling. Consistent with this hypothesis, PTEN expression was down-regulated and phosphoAkt was enriched in CMCs in response to adenoviral-mediated MRTF-A overexpression (Fig. 6A) . The actin-binding protein STARS enhances MRTF-A activity by promoting actin polymerization (7, 8) , thereby releasing MRTF-A from G-actin and allowing its nuclear translocation. Low levels of MRTF-Aexpressing adenovirus only modestly induced Akt signaling whereas STARS did not induce Akt signaling. However, MRTF-A and STARS synergized to induce robust activation of the Aktsignaling pathway, as demonstrated by reduction of PTEN protein levels and phosphorylation of Akt and GSK3β (Fig. 6B) . We note, however, that induction of phospho-Akt by MRTF-A was greater than by overexpression of miR-486, suggesting that MRTF-A may act through additional mechanisms to control this pathway.
To determine whether miR-486 is required for the induction of Akt signaling by MRTF-A, we used 2′ O-Me-modified antisense oligonucleotides to knock down miR-486 expression in CMCs overexpressing MRTF-A. Whereas MRTF-A induced miR-486 expression ∼10-fold, si-miR-486 reduced the level of miR-486 to background levels (Fig. 6C) . Western blot for endogenous PTEN and Foxo1a demonstrated reduced protein levels upon overexpression of MRTF-A, whereas knockdown of miR-486 attenuated the decrease of both PTEN and Foxo1a protein levels (Fig. 6D) . Phospho-Akt showed a corresponding increase in the presence of MRTF-A, whereas Akt phosphorylation was reduced upon knockdown of miR-486 (Fig. 6D ). These results demonstrate that MRTF-A activates the PI3K/Akt-signaling pathway at least partially via the induction of miR-486 and concomitant reduction of PTEN protein levels (Fig. 7) .
Discussion
In this study, we identify a unique muscle-enriched miRNA, miR-486, that enhances PI3K/Akt signaling by repressing expression of PTEN and Foxo1a, which function as negative components of this pathway. The regulation of miR-486 by MRTF-A also reveals a previously unknown role of MRTF-A in the modulation of PI3K/Akt signaling.
Regulation of miR-486 by MRTF-A. miR-486 is generated by processing intronic RNA from the sAnk1 gene, which is directly regulated by SRF/MRTF-A and MyoD. It is intriguing that, although MRTF-A is present in the heart during embryogenesis, miR-486 is not significantly expressed in the ventricle until postnatal day 5. It is possible that the expression of miR-486 is positively or negatively influenced by additional muscle regulatory factors. Indeed, although the full-length intronic enhancer directs MRTF-A responsiveness in vitro, only a truncated construct directs muscle expression in transgenic mice. These results suggest the presence of a negative regulatory element in the 3′ end of the intronic enhancer that may be responsible for temporal or tissue-specific expression of miR-486.
miR-486 joins a collection of muscle-restricted miRNAs with roles in muscle growth, development, and signal responsiveness, many of which are also regulated by SRF together with members of the myocardin family (9, (17) (18) (19) . miR-1 promotes cardiac gene activation in stem cells and inhibits myoblast proliferation, and miR-133 regulates multiple aspects of muscle growth and maturation at least in part through repression of SRF (20, 21, 22) . SRF also regulates the expression of miR-143 and -145, which are expressed specifically in cardiac and smooth muscle cells and mediate multiple steps in actin signaling and SRF function (9, 18) . The integration of miRNAs into the regulatory circuits controlled by SRF and its coactivators provides signal responsiveness to miRNA-regulated networks and also serves to stabilize and modulate SRF-signaling pathways. It remains to be determined if other transcriptional circuits are as reliant on miRNA regulation as SRF-dependent circuits.
Modulation of PI3K/Akt Signaling by MRTF-A and miR-486. The ability of miR-486 to target the mRNAs encoding PTEN and Foxo1a point to this miRNA as a potential regulator of PI3K/Akt signaling in muscle cells. The PI3K/Akt-signaling pathway is integral to the process of postnatal muscle growth and physiological hypertrophy (23) (24) (25) . IGF1 and insulin stimulate hypertrophic growth and glucose uptake via the PI3K-dependent phosphorylation and activation of Akt. Activated Akt results in the phosphorylation-dependent activation of the progrowth protein mTOR, concomitant with a phosphorylation-dependent inhibition of Foxo and GSK3β, negative regulators of protein synthesis and muscle growth (14, 15, 23, 26) . PTEN inhibits PI3K phosphorylation and blocks the subsequent initiation of phospho-Akt-dependent hypertrophic and survival signaling. PTEN deletion in the heart results in exaggerated PI3K/Akt signaling, promoting physiological hypertrophy and preventing maladaptive ventricular remodeling (16).
Although a role for MRTF-A in regulating the physiological hypertrophy of cardiac or skeletal muscle has not yet been reported, MRTF-A expression is increased during exercise-induced hypertrophy (27) and reduced in aged muscles, which display significant atrophy (28) . Moreover, expression of a dominant negative MRTF mutant protein in skeletal muscle causes muscle hypoplasia (29) . In the heart, pathological stimuli up-regulate the expression of STARS, triggering nuclear accumulation of MRTF-A and hypertrophic growth (7, 8) .
Our study identifies miR-486 as a potential link between MRTF-A and the PI3K/Akt-signaling pathway. However, knockdown of miR-486 does not completely block the phosphorylation of Akt, suggesting that MRTF-A may exhibit miR-486-independent mechanisms of Akt activation. miR-486 may also influence both positive and negative aspects of the Akt-signaling pathway, perhaps acting as a buffer to minimize dramatic changes in activity. Indeed, miR-486 is predicted to target positive regulators of the Akt-signaling pathway, including IGF1 and p85α. Negative regulation of IGF1 and p85α by miR-486 would be predicted to counteract the positive influence on the PI3K/ Akt-signaling pathway via inhibition of PTEN and Foxo1a; however, it is currently unclear whether miR-486 regulates these predicted targets. Finally, miR-486 is not limited to the regulation of components of the Akt-signaling pathway because predicted targets include myriad mRNAs involved in a wide range of biological processes.
The expression of miR-486 is altered during the processes of muscle growth and atrophy in a manner consistent with the regulation of muscle hypertrophy. miR-486 levels increase in the heart postnatally, concomitant with the switch from proliferative to hypertrophic growth (30) . Increased miR-486 levels correlate with a decrease in postnatal PTEN levels in the heart, potentially promoting the hypertrophic phase of cardiac growth. Conversely, miR-486 levels decrease in atrophied muscle following denervation (Fig. S7) . The miR-486 target and Akt pathway component, Foxo1a, induces atrophy-associated gene expression in adult skeletal muscle (15, 26) . By impinging on the PI3K/Akt pathway and regulatory subunit, p85α (31) . Likewise, miR-126 regulates angiogenesis at least partially via repression of the PI3K regulatory subunit, p85β (32) . Multiple miRNAs, including miR-21, -26a, -216a, and -217, also appear to positively influence PI3K/Akt signaling by targeting PTEN for inhibition (33) (34) (35) (36) . It is possible that considerable overlap or redundancy exists between miRNAs that maintain the PI3K/Akt pathway in a state of equilibrium under normal conditions. Previous studies have shown that miR-486 is down-regulated in Duchenne's muscular dystrophy (37) , and our results demonstrate that miR-486 is down-regulated during denervation-induced muscle atrophy, suggesting a potential role for miR-486 in muscle atrophy. Pharmacological interventions designed to elevate miR-486 levels during disease states may therefore impede the progression of muscle wasting.
Materials and Methods
RNA Isolation and miRNA Microarray Analysis. RNA was purified from CMCs using TRIzol reagent (Invitrogen), and microRNA microarray analysis was performed using the mammalian microRNA probeset (LC Sciences). Details are described in SI Materials and Methods.
Northern Blot. Ten micrograms of total RNA was loaded onto a denaturing 20% polyacrylamide gel and probed with an antisense STARFIRE probe (IDT) as described in SI Materials and Methods.
In Situ Hybridization. Whole-mount and radioactive section in situ hybridization was performed, using a probe designed against exon 39a of sAnk1. Details are in SI Materials and Methods.
lacZ Reporter Assay. Transgenic mice harboring various fragments of miR-486 regulatory DNA fused to a hsp68-lacZ reporter construct were generated and assayed for β-galactosidase activity as described in SI Materials and Methods.
Surgical Procedures. All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Texas Southwestern Medical Center. Denervation was performed on anesthetized 6-to 8-weekold mice by cutting the left sciatic nerve at the mid-thigh region.
Cell Culture and Luciferase Assay. COS cells were transfected with various expression plasmids and miR-486-luciferase reporter constructs using Fugene 6.0 (Roche) according to the manufacturer's protocol as described in SI Materials and Methods. Primary rat cardiomyocytes were prepared and infected with adenovirus or transfected with siRNA (IDT) as described in SI Materials and Methods.
Electrophoretic Mobility Shift Assay. In vitro binding analysis was performed using conditions and oligonucleotides as described in SI Materials and Methods.
Plasmid Construction. A miR-486 genomic fragment, various putative enhancers of miR-486, and 3′ UTRs of putative miR-486 targets were amplified using LA Taq (TAKARA) and cloned into pCRII-TOPO. Site-directed mutagenesis was carried out using the Quickchange II kit (Stratagene). Details and primer sequences are described in SI Materials and Methods.
Western Blot. Antibodies directed against PTEN, Akt, Akt-phospho-Ser473, GSK3β-phospho-Ser9 (Cell Signaling Technologies), and Foxo1a (Abcam) were used to determine protein level by Western blot. GAPDH (Calbiochem) was detected as loading control. 
